top of page


FDA approves Novo Nordisk Awiqli as first once-weekly basal insulin for children with type 2 diabetes
The FDA has expanded Novo Nordisk's Awiqli approval to children aged 10 years and older with type 2 diabetes, establishing the first once-weekly basal insulin option for this paediatric population.

nuaxia
Oct 282 min read


Novo Nordisk licenses Hengrui's once-weekly oral GLP-1/GIP candidate in deal worth up to $2.6bn
Novo Nordisk has secured rights outside Greater China to Hengrui Pharma's once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596 in a deal worth up to $2.6bn.

nuaxia
Sep 302 min read


Novo Nordisk and Orbis Medicines sign macrocycle discovery deal worth up to $1.4bn
Novo Nordisk and Orbis Medicines have entered a multi-target drug-discovery partnership worth up to $1.4 billion to develop orally bioavailable macrocycle medicines for cardiometabolic disease.

nuaxia
Sep 182 min read


Biocytogen and Whitehawk Partner to Advance Next-Generation Bispecific ADCs
The collaboration combines Biocytogen’s fully human antibody discovery platform with Whitehawk’s ADC expertise to develop novel cancer therapies with enhanced targeting potential.

nuaxia
Jul 93 min read


Novo Nordisk Explores Long-Acting Semaglutide Implant Through Vivani Partnership
The collaboration will evaluate Vivani’s implantable semaglutide technology as Novo Nordisk looks to expand treatment options beyond once-weekly injections.

nuaxia
Jul 93 min read


Novo Nordisk Launches Oral Ozempic in US Diabetes Market
First oral GLP-1 tablet expands cardiovascular-protected diabetes treatment beyond injectable semaglutide

nuaxia
May 61 min read
bottom of page